Trade SAB Biotherapeutics, Inc. - SABS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 4.39 |
| Open* | 4.58 |
| 1-Year Change* | 536.11% |
| Day's Range* | 4.39 - 4.66 |
| 52 wk Range | 3.66-14.50 |
| Average Volume (10 days) | 24.92K |
| Average Volume (3 months) | 206.46K |
| Market Cap | 56.55M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 9.23M |
| Revenue | 4.09M |
| EPS | -5.55 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 4.25 | 0.00 | 0.00% | 4.25 | 4.25 | 4.25 |
| Apr 17, 2024 | 4.39 | -0.19 | -4.15% | 4.58 | 4.66 | 4.39 |
| Apr 16, 2024 | 4.51 | -0.05 | -1.10% | 4.56 | 4.64 | 4.51 |
| Apr 15, 2024 | 4.43 | -0.15 | -3.28% | 4.58 | 4.60 | 4.43 |
| Apr 12, 2024 | 4.58 | -0.07 | -1.51% | 4.65 | 4.69 | 4.50 |
| Apr 11, 2024 | 4.48 | -0.09 | -1.97% | 4.57 | 4.57 | 4.48 |
| Apr 10, 2024 | 4.47 | 0.00 | 0.00% | 4.47 | 4.47 | 4.47 |
| Apr 9, 2024 | 4.25 | -0.19 | -4.28% | 4.44 | 4.46 | 4.23 |
| Apr 8, 2024 | 4.37 | 0.05 | 1.16% | 4.32 | 4.37 | 4.30 |
| Apr 5, 2024 | 4.28 | -0.15 | -3.39% | 4.43 | 4.44 | 4.26 |
| Apr 4, 2024 | 4.34 | -0.14 | -3.13% | 4.48 | 4.48 | 4.17 |
| Apr 3, 2024 | 4.46 | 0.03 | 0.68% | 4.43 | 4.52 | 4.43 |
| Apr 2, 2024 | 4.33 | -0.20 | -4.42% | 4.53 | 4.53 | 4.33 |
| Apr 1, 2024 | 4.26 | -0.22 | -4.91% | 4.48 | 4.48 | 4.24 |
| Mar 28, 2024 | 4.52 | 0.37 | 8.92% | 4.15 | 4.59 | 4.11 |
| Mar 27, 2024 | 4.18 | 0.15 | 3.72% | 4.03 | 4.35 | 4.03 |
| Mar 26, 2024 | 4.14 | -0.09 | -2.13% | 4.23 | 4.23 | 3.98 |
| Mar 25, 2024 | 4.13 | -0.49 | -10.61% | 4.62 | 4.62 | 4.07 |
| Mar 22, 2024 | 4.58 | 0.00 | 0.00% | 4.58 | 4.68 | 4.58 |
| Mar 21, 2024 | 4.67 | -0.10 | -2.10% | 4.77 | 4.77 | 4.58 |
SAB Biotherapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, May 14, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 SAB Biotherapeutics Inc Earnings Release Q1 2024 SAB Biotherapeutics Inc Earnings ReleaseForecast -Previous - |
| Friday, June 28, 2024 | ||
| Time (UTC) 14:00 | Country US
| Event SAB Biotherapeutics Inc Annual Shareholders Meeting SAB Biotherapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 19, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 SAB Biotherapeutics Inc Earnings Release Q2 2024 SAB Biotherapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Total revenue | 23.9042 | 60.8761 | 55.2378 |
| Revenue | 23.9042 | 60.8761 | 55.2378 |
| Total Operating Expense | 52.8218 | 73.6037 | 34.681 |
| Selling/General/Admin. Expenses, Total | 16.3833 | 17.0857 | 6.7723 |
| Research & Development | 36.0325 | 57.1836 | 27.9087 |
| Unusual Expense (Income) | 0 | -0.6656 | 0 |
| Operating Income | -28.9176 | -12.7276 | 20.5568 |
| Interest Income (Expense), Net Non-Operating | -0.23051 | -0.27134 | -0.44302 |
| Other, Net | 10.433 | -4.14558 | 0.004 |
| Net Income Before Taxes | -18.7152 | -17.1445 | 20.1178 |
| Net Income After Taxes | -18.7408 | -17.1445 | 20.1178 |
| Net Income Before Extra. Items | -18.7408 | -17.1445 | 20.1178 |
| Net Income | -18.7408 | -17.1445 | 20.1178 |
| Income Available to Common Excl. Extra. Items | -18.7408 | -17.1445 | 20.1178 |
| Income Available to Common Incl. Extra. Items | -18.7408 | -17.1445 | 20.1178 |
| Diluted Net Income | -18.7408 | -17.1445 | 20.1178 |
| Diluted Weighted Average Shares | 43.525 | 42.9551 | 27.0115 |
| Diluted EPS Excluding Extraordinary Items | -0.43058 | -0.39913 | 0.74479 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||
| Diluted Normalized EPS | -0.43058 | -0.41462 | 0.74479 |
| Depreciation / Amortization | 0.284 | ||
| Interest Expense (Income) - Net Operating | 0.122 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.08552 | 0.5811 | 2.16087 | 3.58971 | 18.1536 |
| Total Operating Expense | 6.56214 | 7.98311 | 10.0209 | 11.397 | 31.4039 |
| Other Operating Expenses, Total | -0.092 | ||||
| Operating Income | -6.47662 | -7.40201 | -7.86001 | -7.80731 | -13.2503 |
| Interest Income (Expense), Net Non-Operating | -0.04675 | -0.0344 | -0.05777 | -0.05324 | -0.1195 |
| Other, Net | -0.35752 | 0.08259 | 0.06881 | 0.78449 | 9.57965 |
| Net Income Before Taxes | -6.88089 | -7.35382 | -7.84897 | -7.07607 | -3.79014 |
| Net Income After Taxes | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Net Income Before Extra. Items | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Net Income | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Income Available to Common Excl. Extra. Items | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Income Available to Common Incl. Extra. Items | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Diluted Net Income | -6.88089 | -7.35382 | -7.8746 | -7.07607 | -3.79014 |
| Diluted Weighted Average Shares | 50.4213 | 50.397 | 44.9728 | 43.0309 | 43.0366 |
| Diluted EPS Excluding Extraordinary Items | -0.13647 | -0.14592 | -0.1751 | -0.16444 | -0.08807 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.13647 | -0.14592 | -0.1751 | -0.16444 | -0.08807 |
| Revenue | 0.08552 | 0.5811 | 2.16087 | 3.58971 | 18.1536 |
| Selling/General/Admin. Expenses, Total | 2.90001 | 3.44739 | 2.88277 | 4.04405 | 9.45647 |
| Research & Development | 3.56813 | 4.44172 | 7.04411 | 7.25698 | 21.7314 |
| Unusual Expense (Income) | 0 | 0 | 0 | ||
| Depreciation / Amortization | 0.023 | 0.025 | 0.186 | 0.025 | 0.073 |
| Interest Expense (Income) - Net Operating | 0.071 | 0.069 | 0.071 | 0.143 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Total Current Assets | 22.0975 | 50.192 | 34.455 |
| Cash and Short Term Investments | 15.0469 | 33.2067 | 12.6104 |
| Cash & Equivalents | 15.0469 | 33.2067 | 12.6104 |
| Total Receivables, Net | 5.55658 | 8.01071 | 20.5695 |
| Accounts Receivable - Trade, Net | 5.55658 | 8.01071 | 20.5695 |
| Prepaid Expenses | 1.49398 | 2.63622 | 1.27513 |
| Other Current Assets, Total | 0 | 6.33831 | 0 |
| Total Assets | 50.9049 | 81.1409 | 56.5379 |
| Property/Plant/Equipment, Total - Net | 28.3398 | 30.949 | 22.0829 |
| Property/Plant/Equipment, Total - Gross | 34.6183 | 34.169 | 23.8501 |
| Accumulated Depreciation, Total | -6.27852 | -3.22002 | -1.76719 |
| Total Current Liabilities | 14.9933 | 26.4553 | 11.0617 |
| Accounts Payable | 3.67912 | 4.45853 | 7.38236 |
| Accrued Expenses | 10.3588 | 13.382 | 2.82914 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.90545 | 1.95777 | 0.73345 |
| Other Current Liabilities, Total | 0.05 | 6.65692 | 0.11678 |
| Total Liabilities | 19.8468 | 42.591 | 17.5301 |
| Total Long Term Debt | 4.17129 | 3.76243 | 4.09559 |
| Long Term Debt | 0.54164 | 0 | 0.17204 |
| Capital Lease Obligations | 3.62964 | 3.76243 | 3.92355 |
| Other Liabilities, Total | 0.68216 | 12.3733 | 2.37278 |
| Total Equity | 31.0581 | 38.5499 | 39.0078 |
| Common Stock | 0.00509 | 0.00435 | 0.0026 |
| Additional Paid-In Capital | 84.4441 | 67.6745 | 50.9897 |
| Retained Earnings (Accumulated Deficit) | -47.8698 | -29.129 | -11.9844 |
| Total Liabilities & Shareholders’ Equity | 50.9049 | 81.1409 | 56.5379 |
| Total Common Shares Outstanding | 50.3943 | 43.4873 | 25.9734 |
| Other Long Term Assets, Total | 0.46769 | 0 | |
| Treasury Stock - Common | -5.52125 | 0 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 3.12771 | 9.00618 | 15.032 | 22.0975 | 22.1821 |
| Cash and Short Term Investments | 2.42548 | 7.77446 | 13.0601 | 15.0469 | 8.33219 |
| Cash | |||||
| Prepaid Expenses | 0.70223 | 0.8676 | 1.20878 | 1.49398 | 0.90787 |
| Total Assets | 28.3363 | 35.4426 | 42.672 | 50.9049 | 52.5075 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 0.37119 | 0.434 | 0.434 | 0.46769 | 0.50139 |
| Total Current Liabilities | 9.21094 | 11.011 | 13.6657 | 14.9933 | 17.1012 |
| Accrued Expenses | 5.79922 | 6.45349 | 8.65427 | 10.3588 | 11.3686 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.0805 | 15.7261 | 18.2695 | 19.8468 | 21.8841 |
| Total Long Term Debt | 3.45244 | 4.0274 | 4.13777 | 4.17129 | 3.66254 |
| Other Liabilities, Total | 0.4171 | 0.68768 | 0.466 | 0.68216 | 1.12029 |
| Total Equity | 15.2558 | 19.7164 | 24.4025 | 31.0581 | 30.6234 |
| Common Stock | 0.00529 | 0.00529 | 0.00509 | 0.00509 | 0.00436 |
| Additional Paid-In Capital | 87.9786 | 87.3369 | 85.1423 | 84.4441 | 76.1355 |
| Retained Earnings (Accumulated Deficit) | -67.2068 | -62.1045 | -55.2236 | -47.8698 | -39.9952 |
| Total Liabilities & Shareholders’ Equity | 28.3363 | 35.4426 | 42.672 | 50.9049 | 52.5075 |
| Total Common Shares Outstanding | 52.3192 | 52.3147 | 50.3978 | 50.3943 | 43.0309 |
| Cash & Equivalents | 2.42548 | 7.77446 | 13.0601 | 15.0469 | 8.33219 |
| Total Receivables, Net | 0 | 0.36412 | 0.76312 | 5.55658 | 12.942 |
| Accounts Receivable - Trade, Net | 0 | 0.36412 | 0.76312 | 5.55658 | 12.942 |
| Other Current Assets, Total | 0 | 0 | |||
| Property/Plant/Equipment, Total - Net | 24.8374 | 26.0024 | 27.206 | 28.3398 | 29.824 |
| Accounts Payable | 1.08317 | 1.40385 | 1.44496 | 3.67912 | 5.48428 |
| Current Port. of LT Debt/Capital Leases | 0.67113 | 0.23892 | 0.57729 | 0.90545 | 0.1659 |
| Other Current Liabilities, Total | 1.65742 | 2.91478 | 2.9892 | 0.05 | 0.0825 |
| Long Term Debt | 0 | 0.54164 | 0.54164 | 0.54164 | |
| Capital Lease Obligations | 3.45244 | 3.48575 | 3.59613 | 3.62964 | 3.66254 |
| Property/Plant/Equipment, Total - Gross | 33.8268 | 34.0894 | 34.383 | 34.6183 | 35.2037 |
| Accumulated Depreciation, Total | -8.98937 | -8.08705 | -7.17698 | -6.27852 | -5.37971 |
| Treasury Stock - Common | -5.52125 | -5.52125 | -5.52125 | -5.52125 | -5.52125 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Net income/Starting Line | -18.7408 | -17.1445 | 20.1178 |
| Cash From Operating Activities | -23.4595 | 1.98687 | 10.0048 |
| Cash From Operating Activities | 3.16943 | 1.48861 | 0.38314 |
| Non-Cash Items | -7.65056 | 5.95965 | 1.45821 |
| Changes in Working Capital | -0.23758 | 11.6831 | -11.9543 |
| Cash From Investing Activities | -2.09002 | -10.9437 | -12.7227 |
| Capital Expenditures | -2.16641 | -10.9437 | -12.7317 |
| Other Investing Cash Flow Items, Total | 0.07639 | 0.009 | |
| Cash From Financing Activities | 1.05141 | 35.8914 | 8.98232 |
| Issuance (Retirement) of Stock, Net | 2.23652 | 34.347 | 10.5618 |
| Issuance (Retirement) of Debt, Net | -1.18511 | 1.54444 | -1.5795 |
| Net Change in Cash | -24.4981 | 26.9346 | 6.26441 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.35382 | -18.7408 | -10.8662 | -3.79013 | 0.98586 |
| Cash From Operating Activities | -1.60572 | -23.4595 | -23.6762 | -15.5026 | -9.53773 |
| Non-Cash Items | 0.63844 | -7.65056 | -8.23501 | -8.05345 | -6.92504 |
| Changes in Working Capital | 4.21121 | -0.23758 | -6.84564 | -5.04444 | -4.32706 |
| Cash From Investing Activities | -0.0213 | -2.09002 | -1.97227 | -1.89377 | -1.28093 |
| Other Investing Cash Flow Items, Total | 0 | 0.07639 | 0.07639 | 0.07639 | 0.07639 |
| Cash From Financing Activities | -0.35979 | 1.05141 | -5.56433 | -5.53216 | -6.31795 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Stock, Net | 0.00189 | 2.23652 | -5.44427 | -5.44428 | -5.51342 |
| Issuance (Retirement) of Debt, Net | -0.36168 | -1.18511 | -0.12005 | -0.08788 | -0.80453 |
| Net Change in Cash | -1.98681 | -24.4981 | -31.2128 | -22.9285 | -17.1366 |
| Cash From Operating Activities | 0.89845 | 3.16943 | 2.27062 | 1.38543 | 0.63624 |
| Capital Expenditures | -0.0213 | -2.16641 | -2.04866 | -1.97016 | -1.35732 |
| Deferred Taxes | 0 | 0.09228 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
SAB Biotherapeutics, Inc. Company profile
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.
Financial summary
BRIEF: For the nine months ended 30 September 2021, SAB Biotherapeutics Inc revenues was not reported. Net income totaled to $440K.
| Industry: | Biotechnology & Medical Research (NEC) |
2100 East 54Th Street North
Suite 202
SIOUX FALLS
SOUTH DAKOTA 57104
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com